Psychopharmacological Treatment Algorithms of Manic/Mixed and Depressed Episodes in Pediatric Bipolar Disorder
- 1 December 2022
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Child and Adolescent Psychopharmacology
- Vol. 32 (10), 507-521
- https://doi.org/10.1089/cap.2022.0035
Abstract
Introduction: Pediatric bipolar disorder (PBD) is a severe psychiatric illness diagnosed before the age of 18, which is associated with extreme shifts in mood characterized by manic and depressive episodes. In 2005, AACAP published algorithms to guide pharmacological treatment of manic/mixed episodes associated with PBD. At that time, lithium was the only Food and Drug Administration (FDA)-approved treatment for pediatric bipolar manic/mixed episodes. The goal of this article is to review evidence that has emerged since the AACAP algorithm in 2005. Methods: Literature searches were conducted through PubMed and limited to studies published between 2005 and 2021, using keywords that focused on randomized controlled trials (RCTs) for available psychopharmacological medications. In addition, the authors conducted in-depth searches for articles providing evidence for agents included in the 2005 AACAP algorithm. Results: Since the publication of the AACAP algorithm in 2005, multiple RCTs have been conducted in PBD, leading to FDA approval of five medications (aripiprazole, asenapine, olanzapine, quetiapine, and risperidone) for the treatment of manic/mixed episodes and two medications (lurasidone and olanzapine-fluoxetine combination) for the treatment of depressed episodes. Divalproex sodium and oxcarbazepine were studied in pediatric RCTs and failed to separate from placebo. Conclusions: We offer an update to the 2005 AACAP algorithms for the treatment of pediatric bipolar mixed/manic episodes and added an evidence-based algorithm for the treatment of depression in PBD. In addition to treatment algorithms, we review current evidence for efficacy of agents proposed in the AACAP algorithm and provide tables summarizing medication side effects and efficacy.Keywords
This publication has 65 references indexed in Scilit:
- Efficacy and Safety of Quetiapine in Children and Adolescents With Mania Associated With Bipolar I DisorderPublished by Physicians Postgraduate Press, Inc ,2013
- Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre studyJournal of Psychiatry and Neuroscience, 2012
- A Randomized Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of Bipolar I Disorder, Manic or Mixed Phase, in Children and AdolescentsArchives of General Psychiatry, 2012
- Meta-Analysis of Epidemiologic Studies of Pediatric Bipolar DisorderBritish Journal of Psychology, 2011
- A double‐blind, placebo‐controlled pilot study of quetiapine for depressed adolescents with bipolar disorderBipolar Disorders, 2009
- Omega-3 Fatty Acids in Depression: A Review of Three StudiesCNS Neuroscience & Therapeutics, 2009
- Why do many psychiatric disorders emerge during adolescence?Nature Reviews Neuroscience, 2008
- Family-Focused Treatment for Adolescents With Bipolar DisorderArchives of General Psychiatry, 2008
- Omega-3 fatty acids for bipolar disorderEmergencias, 2008
- Clozapine Treatment of Children and Adolescents with Bipolar Disorder and Schizophrenia: A Clinical Case SeriesJournal of Child and Adolescent Psychopharmacology, 1995